One melanoma study focused on cancer resistant to inhibitors of BRAF, a commonly mutated protein in melanoma, and showed that a subset is sensitive to TBK1/IKKε inhibition (compound II, along with other inhibitors) [42]. This evidence concerns the gene IKBKE and cancer.